Literature DB >> 27761872

Correlation between indoleamine 2,3 dioxygenase mRNA and CDKN2A/p16 mRNA: a combined strategy to cervical cancer diagnosis.

Mario Cezar Saffi Junior1,2, Ivone da Silva Duarte1, Rodrigo Barbosa de Oliveira Brito1, Giovana Garcia Prado1, Sergio Makabe2, Humberto Dellê1, Cleber P Camacho3.   

Abstract

Cervical cancer (CC) is one of the most common cancers among women worldwide. The relation of the human papillomavirus (HPV) with CC and its precursor lesions was first suspected for over 40 years. The indoleamine 2,3 dioxygenase (IDO) is an immune modulator enzyme responsible for the immune system tissue protection mechanism, which may be the key to the tumoural persistence. HPV oncoprotein E7 promotes the increase in cyclin-dependent kinase inhibitor p16 (CDKN2A/p16). The isolated and combined analysis of CDKN2A/p16 mRNA to CC diagnosis was done with promising results. The aim of this study is to evaluate the correlation between IDO mRNA and CDKN2A/p16 mRNA. We will explore the potential of both as diagnostic tools. RNA was extracted from tissue samples. cDNA was generated with High Capacity RNA-to-cDNA kit. The real-time PCR results were analysed using nonlinear curve estimation, ROC curve, Chi-squared test, the proportion of variance explained and Galen and Gambino formulas. From 270 patients attended, colposcopy examination was performed in 110 and the biopsy in 75 patients. We found a positive correlation in patients older than 28 years old with low-risk lesions, but the correlation is lost in high-risk lesions. Although cytology, IDO mRNA and CDKN2A/p16 mRNA could not differentiate the risk groups, IDO combined with CDKN2A/p16 mRNA results could (p = 0.028). The best diagnostic result was achieved by IDO coupled with CDKN2A/p16 mRNA, which may considerably increase the sensitivity of screening for CC.

Entities:  

Keywords:  CDKN2A; Cervical cancer; Cytology; IDO; Screening program; mRNA

Mesh:

Substances:

Year:  2016        PMID: 27761872     DOI: 10.1007/s12032-016-0844-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  38 in total

1.  Analysis of Kynurenine/Tryptophan ratio and expression of IDO1 and 2 mRNA in tumour tissue of cervical cancer patients.

Authors:  Jayakumar Hascitha; Ramanathan Priya; Subramani Jayavelu; Hemavathi Dhandapani; Ganeshrajah Selvaluxmy; Shirley Sunder Singh; Thangarajan Rajkumar
Journal:  Clin Biochem       Date:  2016-04-20       Impact factor: 3.281

2.  Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.

Authors:  Gottfried E Konecny; Chen Wang; Habib Hamidi; Boris Winterhoff; Kimberly R Kalli; Judy Dering; Charles Ginther; Hsiao-Wang Chen; Sean Dowdy; William Cliby; Bobbie Gostout; Karl C Podratz; Gary Keeney; He-Jing Wang; Lynn C Hartmann; Dennis J Slamon; Ellen L Goode
Journal:  J Natl Cancer Inst       Date:  2014-09-30       Impact factor: 13.506

3.  Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy.

Authors:  Tomoko Inaba; Kazuhiko Ino; Hiroaki Kajiyama; Kiyosumi Shibata; Eiko Yamamoto; Shinji Kondo; Tomokazu Umezu; Akihiro Nawa; Osamu Takikawa; Fumitaka Kikkawa
Journal:  Gynecol Oncol       Date:  2010-03-28       Impact factor: 5.482

4.  Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival.

Authors:  Debbie M Ferns; Ido P Kema; Marrije R Buist; Hans W Nijman; Gemma G Kenter; Ekaterina S Jordanova
Journal:  Oncoimmunology       Date:  2015-02-25       Impact factor: 8.110

5.  Infiltrating cellular pattern in kidney graft biopsies translates into forkhead box protein 3 up-regulation and p16INK4α senescence protein down-regulation in patients treated with belatacept compared to cyclosporin A.

Authors:  J Furuzawa-Carballeda; G Lima; J Alberú; D Palafox; N Uribe-Uribe; L E Morales-Buenrostro; R Reyes Acevedo; G Mondragón; A Chevaile; L Llorente
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

6.  The association of p16(INK4A) and fragile histidine triad gene expression and cervical lesions.

Authors:  Adhemar Longatto-Filho; Daniela Etlinger; Sônia Maria Miranda Pereira; Cristina Takami Kanamura; Celso di Loreto; Gilda da Cunha Santos; Sérgio Makabe; José A Marques; Carmen L F Santoro; Gerson Botacini das Dores; Adauto Castelo
Journal:  J Low Genit Tract Dis       Date:  2007-07       Impact factor: 1.925

7.  A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection.

Authors:  L A Koutsky; K K Holmes; C W Critchlow; C E Stevens; J Paavonen; A M Beckmann; T A DeRouen; D A Galloway; D Vernon; N B Kiviat
Journal:  N Engl J Med       Date:  1992-10-29       Impact factor: 91.245

8.  Indoleamine 2,3-dioxygenase: distribution and function in the developing human placenta.

Authors:  Yoshiki Kudo; C A R Boyd; Isabella Spyropoulou; C W G Redman; Osamu Takikawa; Takafumi Katsuki; Tetsuaki Hara; Koso Ohama; I L Sargent
Journal:  J Reprod Immunol       Date:  2004-04       Impact factor: 4.054

9.  Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica.

Authors:  Sophia S Wang; Marcus Trunk; Mark Schiffman; Rolando Herrero; Mark E Sherman; Robert D Burk; Allan Hildesheim; M Concepcion Bratti; Tom Wright; Ana Cecilia Rodriguez; Sabrina Chen; Anja Reichert; Christina von Knebel Doeberitz; Ruediger Ridder; Magnus von Knebel Doeberitz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-08       Impact factor: 4.254

10.  Expression of P16 in high-risk human papillomavirus related lesions of the uterine cervix in a government hospital, Malaysia.

Authors:  Purushotham Krishnappa; Ibtisam Binti Mohamad; Yip Jo Lin; Ankur Barua
Journal:  Diagn Pathol       Date:  2014-11-01       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.